IN2012DN02968A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02968A
IN2012DN02968A IN2968DEN2012A IN2012DN02968A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A IN 2968DEN2012 A IN2968DEN2012 A IN 2968DEN2012A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A
Authority
IN
India
Prior art keywords
present
relates
heterocyclic
schizophrenia
solvate
Prior art date
Application number
Other languages
English (en)
Inventor
Paul David Ratcliffe
Thomas Russell Clarkson
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of IN2012DN02968A publication Critical patent/IN2012DN02968A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN2968DEN2012 2009-10-13 2010-10-11 IN2012DN02968A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (fr) 2009-10-13 2010-10-11 Dérivés condensés d'azine pour le traitement de maladies liées aux récepteurs de l'acétylcholine

Publications (1)

Publication Number Publication Date
IN2012DN02968A true IN2012DN02968A (fr) 2015-07-31

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2968DEN2012 IN2012DN02968A (fr) 2009-10-13 2010-10-11

Country Status (12)

Country Link
US (1) US8841289B2 (fr)
EP (1) EP2488520B1 (fr)
JP (1) JP2013507417A (fr)
KR (1) KR20120100913A (fr)
CN (1) CN102666540A (fr)
AU (1) AU2010305825A1 (fr)
BR (1) BR112012008518A2 (fr)
CA (1) CA2776835A1 (fr)
IN (1) IN2012DN02968A (fr)
MX (1) MX2012004289A (fr)
RU (1) RU2012119488A (fr)
WO (1) WO2011045258A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843383A1 (fr) 2011-07-29 2013-02-07 Taisho Pharmaceutical Co., Ltd. Compose d'amidine ou sel de celui-ci
WO2013132253A1 (fr) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) Composés 3-aryl -5-substitué-isoquinolin -1-one et leur utilisation thérapeutique
EP2852382A1 (fr) * 2012-05-22 2015-04-01 King Abdullah University Of Science And Technology Combinaison comprenant du parthenolide pour le traitement de la maladie d'alzheimer et d'autres troubles neurodégénératifs
CN105722835B (zh) 2013-09-11 2018-07-31 癌症研究协会:皇家癌症医院 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
WO2016034703A1 (fr) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Composés hétérocycliques ou carbocycliques condensés portant un radical cycloaliphatique substitué et leur utilisation pour traiter les maladies liées à la vasopressine
JP6612874B2 (ja) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
WO2016126926A1 (fr) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine
EP3253759A1 (fr) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
DK3386591T3 (da) * 2015-12-09 2020-09-28 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
WO2017100593A1 (fr) 2015-12-09 2017-06-15 Luc Therapeutics Modulateurs de récepteurs nmda de type thiénopyrimidinone et utilisations associées
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
EA202190116A1 (ru) * 2018-06-27 2021-08-30 Реборна Биосайенсиз, Инк. Агент для профилактики или лечения спинальной мышечной атрофии
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
JP2022511236A (ja) 2018-07-26 2022-01-31 ドメイン・セラピューティクス 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
BR112021001967A2 (pt) 2018-08-03 2021-04-27 Cadent Therapeutics, Inc. moduladores de receptor nmda heteroaromáticos e usos dos mesmos
WO2021198188A1 (fr) 2020-03-30 2021-10-07 Enyo Pharma Dérivés de quinazolinone et leurs utilisations pour le traitement d'un cancer
WO2021198191A1 (fr) 2020-03-30 2021-10-07 Enyo Pharma Dérivés de quinazolinone et leurs utilisations pour le traitement d'un cancer
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2024054591A1 (fr) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CA2444598A1 (fr) * 2001-04-20 2003-10-31 Vertex Pharmaceuticals Incorporated Compositions utiles comme inhibiteurs de la gsk-3
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CA2615577C (fr) * 2005-07-26 2014-09-09 Sanofi-Aventis Derives de l'isoquinolone substitutee en piperidinyl en tant qu'inhibiteurs de la rho-kinase
CA2663161C (fr) 2006-09-11 2014-10-28 N.V. Organon Derives d'acetamide de quinazolinone et d'isoqiinolinone
CN101573354B (zh) * 2006-12-27 2014-02-12 塞诺菲-安万特股份有限公司 取代的异喹啉类及其作为Rho-激酶抑制剂的用途
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
MX2010005040A (es) * 2007-11-14 2010-05-21 Neurosearch As Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil-pirimidina y su uso medico.
WO2009107236A1 (fr) 2008-02-29 2009-09-03 テクノコアインターナショナル株式会社 Dispositif de charge et dispositif de jugement de qualité de bloc-pile

Also Published As

Publication number Publication date
BR112012008518A2 (pt) 2016-04-05
JP2013507417A (ja) 2013-03-04
KR20120100913A (ko) 2012-09-12
US8841289B2 (en) 2014-09-23
CA2776835A1 (fr) 2011-04-21
CN102666540A (zh) 2012-09-12
EP2488520B1 (fr) 2015-09-02
RU2012119488A (ru) 2013-11-20
EP2488520A1 (fr) 2012-08-22
MX2012004289A (es) 2012-06-12
WO2011045258A1 (fr) 2011-04-21
AU2010305825A1 (en) 2012-04-19
US20120208796A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
IN2012DN02968A (fr)
WO2011051490A3 (fr) Dérivés hétérocycliques
IN2014DN03206A (fr)
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
WO2009050242A3 (fr) Pipérazino-dihydrothiénopyrimidines substituées par un hétérocycle
MX2014015158A (es) Derivados de piridinona y piridazinona.
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009010407A (es) Derivados fluorados de deferiprona.
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
WO2008023258A8 (fr) Dérivés de pipéridine
MX2010004686A (es) Derivados heterociclicos.
MX2010002900A (es) Derivados heterociclicos triciclicos.
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
MX2010012189A (es) Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
MX2017008495A (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
PH12016500197B1 (en) Biphenyl derivative and method for preparing same